Drugs

, Volume 63, Issue 20, pp 2157–2168

Appropriate Empirical Antibacterial Therapy for Nosocomial Infections

Getting it Right the First Time
Current Opinion

Abstract

The increasing presence of drug-resistant bacterial infections among hospitalised patients has resulted in greater numbers of patients receiving inappropriate antimicrobial treatment. This has led to the development of a novel paradigm guiding the administration of empirical antimicrobial therapy for patients with serious infections in the hospital setting. Antibacterial de-escalation is an approach to antibacterial utilisation that attempts to balance the need to provide appropriate, initial antibacterial treatment while limiting the emergence of antibacterial resistance. The goal of de-escalation is to prescribe an initial antibacterial regimen that will cover the most likely bacterial pathogens associated with infection while minimising the emergence of antibacterial resistance. Antibacterial resistance is minimised by narrowing the antibacterial regimen once the pathogens and their susceptibility profiles are determined, and by employing the shortest course of therapy clinically acceptable.

References

  1. 1.
    Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: a challenge to hospital leadership. JAMA 1996; 275: 234–40PubMedCrossRefGoogle Scholar
  2. 2.
    Gold HS, Moellering RC. Antimicrobial-drug resistance. N Engl J Med 1996; 335: 1445–53PubMedCrossRefGoogle Scholar
  3. 3.
    Shlaes DM, Gerding DN, John Jr JF, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25: 584–99PubMedCrossRefGoogle Scholar
  4. 4.
    Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) study. EPIC International Advisory Committee. JAMA 1995; 274: 639–44Google Scholar
  5. 5.
    Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in medical intensive care units in the United States: National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27: 887–92PubMedCrossRefGoogle Scholar
  6. 6.
    Quinn JP. Clinical problems posed by multiresistant nonfermenting gram-negative pathogens. Clin Infect Dis 1998; 27 Suppl. 1: S117–24PubMedCrossRefGoogle Scholar
  7. 7.
    Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 349: 493–501CrossRefGoogle Scholar
  8. 8.
    Centers for Disease Control. Staphylococcus aureus resistant to vancomycin: United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51: 565–6Google Scholar
  9. 9.
    Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157: 531–9PubMedGoogle Scholar
  10. 10.
    Fridkin SK, Pear SM, Williamson TH, et al. The role of understaffing in central venous catheter-associated bloodstream infections. Infect Control Hosp Epidemiol 1996; 17: 150–8PubMedCrossRefGoogle Scholar
  11. 11.
    Hardbarth S, Sudre P, Dharan S, et al. Outbreak of Enterobacter cloacae related to understaffing, overcrowding, and poor hygiene practices. Infect Control Hosp Epidemiol 1999; 20: 598–603CrossRefGoogle Scholar
  12. 12.
    Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000; 31 Suppl. 4: S131–8PubMedCrossRefGoogle Scholar
  13. 13.
    Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462–74PubMedCrossRefGoogle Scholar
  14. 14.
    Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118: 146–55PubMedCrossRefGoogle Scholar
  15. 15.
    Cosgrove SE, Kaye KS, Eliopoulous GM, et al. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002; 162: 185–90PubMedCrossRefGoogle Scholar
  16. 16.
    Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998; 113: 412–20PubMedCrossRefGoogle Scholar
  17. 17.
    Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996; 22: 387–94Google Scholar
  18. 18.
    Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111: 676–85PubMedCrossRefGoogle Scholar
  19. 19.
    Winzer K, Williams P. Quorum sensing and the regulation of virulence gene expression in pathogenic bacteria. Int J Med Microbiol 2001; 291: 131–43PubMedCrossRefGoogle Scholar
  20. 20.
    Dufour P, Gillet Y, Bes M, et al. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002; 35: 819–24PubMedCrossRefGoogle Scholar
  21. 21.
    Selvey LA, Whitby M, Johnson B. Nosocomial methicillin-resistant Staphyiococcus aureus bacteremia: is it any worse than nosocomial methicillin-sensitive Staphyiococcus aureus bacteremia? Infect Control Hosp Epidemiol 2000; 21: 645–8PubMedCrossRefGoogle Scholar
  22. 22.
    Hauser AR, Cobb E, Bodi M, et al. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 2002; 30: 521–8PubMedCrossRefGoogle Scholar
  23. 23.
    Roy-Burman A, Savel RH, Racine S, et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001; 183: 1767–74PubMedCrossRefGoogle Scholar
  24. 24.
    Leibovici L, Shraga I, Drucker M, et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244: 379–86PubMedCrossRefGoogle Scholar
  25. 25.
    Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115: 585–90PubMedGoogle Scholar
  26. 26.
    Morin CA, Hadler JL. Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998. J Infect Dis 2001; 184: 1029–34PubMedCrossRefGoogle Scholar
  27. 27.
    Carmeli Y, Troillet N, Karchmer AW, et al. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999; 159: 1127–32PubMedCrossRefGoogle Scholar
  28. 28.
    Webb M, Riley LW, Roberts RB. Cost of hospitalization for and risk factors associated with vancomycin-resistant Enterococcus faecium infection and colonization. Clin Infect Dis 2001; 33: 445–52PubMedCrossRefGoogle Scholar
  29. 29.
    Howard D, Cordell R, McGowan Jr JE, et al. Workshop Group: measuring the economic costs of antimicrobial resistance in hospital settings. Summary of the Centers for Disease Control and Prevention-Emory Workshop. Clin Infect Dis 2001; 33: 1573–8Google Scholar
  30. 30.
    Niederman MS. Appropriate use of antimicrobial agents: challenges and strategies for improvement. Crit Care Med 2003; 31: 608–16PubMedCrossRefGoogle Scholar
  31. 31.
    Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med 2001; 134: 298–314PubMedGoogle Scholar
  32. 32.
    Hoffken G, Neiderman MS. Nosocomial pneumonia: the importance of a de-escalation strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002; 122: 2183–96PubMedCrossRefGoogle Scholar
  33. 33.
    Kollef MH. Hospital-acquired pneumonia and de-escalation of antimicrobial treatment. Crit Care Med 2001; 29: 1473–5PubMedCrossRefGoogle Scholar
  34. 34.
    Rello J, Sa-Borges M, Correa H, et al. Variations in etiology of ventilator-associated pneumonia across four treatment sites. Am J Respir Crit Care Med 1999; 160: 608–13PubMedGoogle Scholar
  35. 35.
    Namias N, Samiian L, Nino D, et al. Incidence and susceptibility of pathogenic bacteria vary between intensive care units within a single hospital: implications for empiric antibiotic strategies. J Trauma 2000; 49: 638–45PubMedCrossRefGoogle Scholar
  36. 36.
    Gruson D, Hibert G, Vargas F, et al. Rotation and restricted use of antibiotics in a medical intensive care unit: impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant gram-negative bacteria. Am J Respir Crit Care Med 2000; 162: 837–43PubMedGoogle Scholar
  37. 37.
    Ibrahim EH, Ward S, Sherman G, et al. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29: 1109–15PubMedCrossRefGoogle Scholar
  38. 38.
    Friedman ND, Kaye KS, Stout JE, et al. Health-care associated bloodstream infection in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137: 791–7PubMedGoogle Scholar
  39. 39.
    Gaynes R. Health-care associated bloodstream infections: a change in thinking. Ann Intern Med 2002; 137: 850–1PubMedGoogle Scholar
  40. 40.
    Mylotte JM. Nursing home-acquired pneumonia. Clin Infect Dis 2002; 35: 1205–11PubMedCrossRefGoogle Scholar
  41. 41.
    Hutt E, Kramer AM. Evidence-based guidelines for management of nursing home-acquired pneumonia. J Fam Pract 2002; 51: 709–16PubMedGoogle Scholar
  42. 42.
    American Thoracic Society. Hospital-acquired pneumonia: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies; a consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med 1996; 153: 1711–25Google Scholar
  43. 43.
    Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002; 122: 2115–21PubMedCrossRefGoogle Scholar
  44. 44.
    Siegman-Igra Y, Ravona R, Primerman H, et al. Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Int J Infect Dis 1998; 2: 211–5PubMedCrossRefGoogle Scholar
  45. 45.
    Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997; 41: 1127–33PubMedGoogle Scholar
  46. 46.
    Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multi-center, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastin: the Severe Pneumonia Study Group. Antimicrob Agents Chemother 1994; 38: 547–57PubMedCrossRefGoogle Scholar
  47. 47.
    Cometta A, Baumgartner JD, Lew D, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneu-tropenic patients. Antimicrob Agents Chemother 1994; 38: 1309–13PubMedCrossRefGoogle Scholar
  48. 48.
    Sieger B, Berman SJ, Geckler RW, et al. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Crit Care Med 1997; 25: 1663–70PubMedCrossRefGoogle Scholar
  49. 49.
    Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122: 262–8PubMedCrossRefGoogle Scholar
  50. 50.
    Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar AE, et al. Impact of the outcome of adequate empirical antibiotherapy in patients admitted to the ICU for sepsis. Crit Care Med. In pressGoogle Scholar
  51. 51.
    Leone M, Bourgoin A, Cambon S, et al. Empirical antimicrobial therapy of septic shock patients: adequacy and impact on outcome. Crit Care Med 2003; 31: 462–7PubMedCrossRefGoogle Scholar
  52. 52.
    Evans RS, Classen DC, Pestotnik SL, et al. Improving empiric antibiotic selection using computer decision support. Arch Intern Med 1994; 154: 878–84PubMedCrossRefGoogle Scholar
  53. 53.
    Evans RS, Pestotnik SL, Classen DC, et al. A computer-assisted management program for antibiotics and other antiinfective agents. N Engl J Med 1998; 338: 232–8PubMedCrossRefGoogle Scholar
  54. 54.
    Bailey TC, Ritchie DJ, McMullin ST, et al. A randomized, prospective evaluation of an interventional program to discontinue intravenous antibiotics at two tertiary care teaching institutions. Pharmacotherapy 1997; 17: 277–81PubMedGoogle Scholar
  55. 55.
    Leibovici L, Gitelman V, Yehezkelli Y, et al. Improving empirical antibiotic treatment: prospective, nonintervention testing of a decision support system. J Intern Med 1997; 242: 395–400PubMedCrossRefGoogle Scholar
  56. 56.
    Singh N, Rogers P, Atwood CW, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: a proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162: 505–11PubMedGoogle Scholar
  57. 57.
    Dennesen PJ, van der Ven AJ, Kessels AG, et al. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001; 163: 1371–5PubMedGoogle Scholar
  58. 58.
    Chastre J, Wolff M, Fagon JY, et al. Comparison of two durations of antibiotic therapy to treat ventilator-associated pneumonia (VAP) [abstract]. Am J Respir Crit Care Med 2003; 167: A21Google Scholar
  59. 59.
    Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280: 1233–7PubMedCrossRefGoogle Scholar
  60. 60.
    Kollef MH, Vlasnik J, Sharpless L, et al. Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156: 1040–8PubMedGoogle Scholar
  61. 61.
    Kollef MH, Ward S, Sherman G, et al. Inadequate treatment of nosocomial infections is associated with certain antibiotic choices. Crit Care Med 2000; 28: 3456–64PubMedCrossRefGoogle Scholar
  62. 62.
    Kollef MH. Is there a role for antibiotic cycling in the intensive care unit? Crit Care Med 2001; 29 (4 Suppl.): N135–42PubMedCrossRefGoogle Scholar
  63. 63.
    Gerding DN, Larson TA, Hughes RA, et al. Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother 1991; 35: 1284–90PubMedCrossRefGoogle Scholar
  64. 64.
    Gruson D, Hilbert G, Vargas F, et al. Strategy of antibiotic rotation: long term effect on the incidence and the susceptibilities of gram-negative bacilli responsible for ventilator-associated pneumonia. Crit Care Med 2003; 31: 1908–14PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.Pulmonary and Critical Care DivisionWashington University School of MedicineSt LouisUSA

Personalised recommendations